VOR vs SANA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
VOR Captures Institutional Edge (3โ1 Pillars ยท 5โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vor Biopharma Inc. Common Stock (VOR) driven by superior Valuation, Momentum & Technical, Options & Structure while SANA counters with relative strength in Growth & Margin. Fundamentally, VOR trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus SANA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, VOR sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against SANA sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VOR | SANA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.2B | $605.3M | Larger Scale | VOR |
| Trailing P/E Ratio Valuation | 0.1x | N/M | Lower Multiple | VOR |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -125.4% | -79.5% | Higher ROE | SANA |
| 52-Week Range Position Momentum | 64% ($6โ$26) | 1% ($2โ$5) | Stronger Trend | VOR |
| Beta / 30D Volatility Risk Regime | 1.90ฮฒ ยท 61% Vol | 1.82ฮฒ ยท 78% Vol | Lower Realized Risk | VOR |
| Unified Institutional Score Composite Signal | 57.8 / 100 (HOLD) | 44.3 / 100 (HOLD) | Higher Composite | VOR |